Index of tables

Please note: due to continuous updates being made to the Immunisation Handbook, the page number on the electronic version will not always match the hard copy version.

• Table 1.3.1: Pre-vaccination screening checklist
• Table 1.3.2: Responses to relevant conditions or circumstances identified by the pre-vaccination screening checklist
• Table 1.3.3: Live attenuated parenteral and oral vaccines
• Table 1.3.4: False contraindications to vaccination
• Table 1.3.5: Number of vaccine doses that should have been administered by the current age of the child (table to be used in conjunction with Catch-up Worksheet)
• Table 1.3.6: Minimum dose intervals for NIP vaccines for children <8 years of age (table to be used in conjunction with Catch-up Worksheet)
• Table 1.3.7: Minimum age for the first dose of vaccine in exceptional circumstances
• Table 1.3.8: Recommendations for Hib catch-up vaccination for children <5 years of age when doses have been delayed or missed
• Table 1.3.9: Recommendations for pneumococcal catch-up vaccination for low-risk children (including Indigenous children living in ACT, NSW, VIC and TAS) <2 years of age, when doses have been delayed or missed
• Table 1.3.10: Recommendations for pneumococcal catch-up vaccination for Indigenous children <2 years of age in NT, QLD, SA and WA, when doses have been delayed or missed
• Table 1.3.11: Recommendations for pneumococcal catch-up vaccination for children ≤5 years of age with underlying medical conditions
• Table 1.3.12: Catch-up schedules for individuals ≥8 years of age
• Table 1.4.1: Route of administration for vaccines commonly used in Australia
• Table 1.4.2: Recommended needle size, length and angle for administering vaccines
• Table 1.5.1: Clinical features which may assist differentiation between a vasovagal episode and anaphylaxis
• Table 1.5.2: Doses of intramuscular 1:1000 (one in one thousand) adrenaline for anaphylaxis
• Table 1.5.3: Contact details for notification of AEFI
• Table 2.2.1: Dose and routes of administration of commonly used vaccines in adult travellers (≥15 years of age)
• Table 2.2.2: Recommended lower age limits of travel vaccines for children
• Table 2.3.1: Vaccinations in pregnancy
• Table 2.3.2: Recommendations for vaccinations for solid organ transplant (SOT) recipients
• Table 2.3.3: Post-transplantation vaccination schedules for allogeneic and autologous haematopoietic stem cell transplant recipients
• Table 2.3.4: Immunological categories based on age-specific CD4 counts and percentage of total lymphocytes
• Table 2.3.5: Recommended intervals between either immunoglobulins or blood products and MMR, MMRV or varicella vaccination
• Table 2.3.6: Recommended vaccinations for those at risk of occupationally acquired vaccine-preventable diseases
• Table 3.1.1: Summary of Australian bat lyssavirus and rabies post-exposure treatment for non-immune individuals
• Table 3.5.1: Recommended dosages and schedules for use of the inactivated hepatitis A vaccines
• Table 3.5.2: Recommended doses of normal human immunoglobulin (NHIG) to be given as a single intramuscular injection to close contacts of hepatitis A cases
• Table 3.6.1: Hepatitis B and hepatitis A/hepatitis B combination vaccination schedules
• Table 3.6.2: Accelerated hepatitis B vaccination schedules
• Table 3.6.3: Post-exposure prophylaxis for non-immune individuals exposed to an HBsAg positive person
• Table 3.9.1: Recommended doses of influenza vaccine
• Table 3.11.1: Management of significant measles exposure using vaccination or normal human immunoglobulin (NHIG)
• Table 3.12.1: Early clinical management of suspected meningococcal disease
• Table 3.14.1: Recommended antimicrobial therapy and chemoprophylaxis regimens for pertussis in infants, children and adults
• Table 3.15.1: Summary table – pneumococcal vaccination schedule for children ≤9 years of age (see also Section 1.3.5, Catch-up)
• Table 3.15.2: Underlying medical conditions predisposing children ≤9 years of age to IPD
• Table 3.15.3: Revaccination with 23vPPV for people ≥10 years of age
• Table 3.17.1: Interpretation and action for serological and skin test results
• Table 3.18.1: Age limits for dosing of oral rotavirus vaccines
• Table 3.21.1: Guide to tetanus prophylaxis in wound management
• Table 3.24.1: Recommendations for varicella vaccination with monovalent VV (currently available), and once MMRV vaccines are available
• Table 3.24.2: Zoster immunoglobulin-VF (ZIG) dose based on weight
• Table 3.25.1: Yellow fever endemic countries